SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Aug. 1, 2006--diaDexus, Inc. today announced the publication of the first recommendations for a proposed cut point for lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme that independently predicts the risk of coronary heart disease and ischemic stroke. The report was published in the Summer 2006 issue of Preventive Cardiology.
